Table 1.
Synergistic combinations of fadraciclib and venetoclax.
| Combination Index | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Fraction Affected | no BCA medium | with BCA medium | del17p with BCA medium | |||||||
| #52 | #54 | #55 | #52 | #54 | #55 | #53 | #56 | #57 | #77 | |
| 0.5 | 4.1 | 0.1 | 0.04 | 3.0 | 0.6 | 1.0 | 0.5 | 0.6 | 0.03 | 0.003 |
| 0.75 | 1.8 | 0.1 | 0.1 | 1.0 | 0.5 | 0.8 | 0.5 | 0.5 | 0.003 | 0.0003 |
| 0.9 | 0.8 | 0.1 | 0.2 | 0.6 | 0.4 | 0.6 | 0.5 | 0.5 | 2.4E-04 | 5.0E-05 |
| 0.99 | 0.1 | 0.2 | 1.8 | 0.5 | 0.3 | 0.4 | 0.6 | 0.8 | 1.3E-06 | 2.0E-07 |
| Dose Reduction Indexa for Fadraciclib | ||||||||||
| Fraction Affected | no BCA medium | with BCA medium | del17p with BCA medium | |||||||
| #52 | #54 | #55 | #52 | #54 | #55 | #53 | #56 | #57 | #77 | |
| 0.5 | 0.4 | 11.3 | 27.0 | 0.4 | 3.3 | 1.4 | 2.5 | 3.9 | 6374.2 | 660.3 |
| 0.75 | 0.8 | 12.6 | 10.7 | 2.0 | 3.9 | 2.0 | 2.2 | 3.0 | 1.9E + 05 | 2.8E + 04 |
| 0.9 | 1.7 | 14.1 | 4.3 | 10.0 | 4.7 | 2.8 | 2.0 | 2.4 | 5.8E + 06 | 1.2E + 06 |
| 0.99 | 9.1 | 18.0 | 0.6 | 326.3 | 7.0 | 3.5 | 1.7 | 1.4 | 9.7E + 09 | 4.0E + 09 |
| Dose Reduction Indexa for Venetoclax | ||||||||||
| Fraction Affected | no BCA medium | with BCA medium | del17p with BCA medium | |||||||
| #52 | #54 | #55 | #52 | #54 | #55 | #53 | #56 | #57 | #77 | |
| 0.5 | 0.8 | 122.7 | 2192.0 | 1.9 | 3.5 | 3.4 | 10.4 | 2.9 | 34.0 | 965.2 |
| 0.75 | 1.9 | 58.8 | 1395.6 | 1.9 | 4.0 | 3.7 | 26.5 | 5.3 | 376.2 | 4492.0 |
| 0.9 | 4.5 | 28.1 | 888.5 | 1.9 | 4.5 | 4.0 | 67.7 | 9.4 | 4137.4 | 2.1E + 04 |
| 0.99 | 29.4 | 5.6 | 331.6 | 1.9 | 5.9 | 4.3 | 523.7 | 33.9 | 7.9E + 05 | 6.0E + 05 |
aThe dose reduction index is a measure of how many fold the dose of each drug in a synergistic combination may be reduced, at a given effect level, compared with the doses of each drug alone.